Adial September vote will decide whether preferred shares convert to common stock
Adial Pharmaceuticals, which spent years developing addiction treatments, completed a pivot in June 2026 when it acquired Azora Therapeutics and took on a drug candidate for ulcerative colitis. A September 17 stockholder vote will determine whether 12.9 million shares of Series